NTRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Natera Inc (NTRA) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company shows strong growth potential, positive financial trends, and bullish analyst sentiment, making it a compelling investment opportunity.
The technical indicators show a neutral to slightly bearish trend in the short term. The MACD is negatively contracting, RSI is neutral at 34.053, and moving averages are converging. Key support is at $198.548, and resistance is at $231.064. The stock is trading pre-market at $207.875, close to its support level, which may present a favorable entry point for long-term investors.
Hedge funds are significantly increasing their positions, with a 265.72% increase in buying over the last quarter.
Analysts have consistently raised price targets, with the latest targets ranging from $205 to $300, and all maintaining Buy or Overweight ratings.
The EDEN study launch for prenatal screening could drive future growth and innovation.
Strong financial performance in Q3 2025, with revenue up 34.66% YoY and gross margin improving to 64.91%.
The MACD is still negative, indicating a lack of strong upward momentum in the short term.
The stock's RSI is neutral, suggesting no immediate bullish signal.
No recent congress trading data or influential figure activity to provide additional sentiment boost.
In Q3 2025, Natera reported revenue growth of 34.66% YoY to $592.18M. Net income improved significantly, up 177.11% YoY to -$87.54M. EPS increased by 146.15% YoY to -$0.64, and gross margin rose to 64.91%, up 5.05% YoY. These metrics indicate strong operational improvements and growth potential.
Analysts are highly bullish on Natera. Recent ratings include Buy ratings from Citi, TD Cowen, Guggenheim, and others, with price targets ranging from $205 to $300. Analysts cite the company's dominant position in molecular residual disease and strong fundamentals as key drivers for future growth.
